2021 AF Symposium: 5 New Summary Reports Posted
I’ve completed several new reports on presentations made at the 2021 AF Symposium. With each report, I strive to share the current state of the art in A-Fib research and treatments and what’s relevant to patients with Atrial Fibrillation. Symposium presenters are the best clinicians and researchers working in Atrial Fibrillation today. My new reports include:
Two Spotlight Sessions on New Technologies/Drugs: A new antiarrhythmic drug in development, and an inhaler that delivers Flecainide for fast results.
Two Clinical Trials: Results comparing the effectiveness of CryoBalloon ablation vs. Drug Therapy; and Findings from the ATTEST trial.
Research: The role of anticoagulants in A-Fib patients who develop cognitive impairment, cerebral microbleeds and dementia entitled “Cerebral Amyloid Angiopathy (CAA).
The new reports (with links):
• Spotlight Session: New Technologies and Drugs―Flecainide Inhaler by InCarda Therapeutics
• Spotlight Session: Drug in Development from Acesion Pharma
• Anticoagulants and Cerebral Amyloid Angiopathy (CAA): Prevalence, Detection and Management
• ATTEST Trial: Catheter Ablation to Modify Progression of AF
• Another Study Finds Ablation Better First-Line Treatment Than Medication
Look for more of my reports from the 2021 AF Symposium in the next weeks and months. And, as always, my reports are written in plain language for A-Fib patients and their families.
Go to my list of all 2021 AF Symposium Reports